MetaCap

BeOne Medicines Ltd. ADR (ONC)

NASDAQ: ONCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

390.94-8.76 (-2.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ONC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$44.66B
52-week range
253.95 – 424.73
Day range
385.00 – 399.76
Volume / Avg
356.78K / 392.74K
Beta
—

52-week range

$253.95$424.73

ONC stock today

Shares of BeOne Medicines (ONC) finished lower on Nov 20 at $390.94, a drop of 2.19% or $8.76 per share, versus the S&P 500's 3.70% decline. At this level, ONC sits near the top of its 52-week range of $253.95 to $424.73: 8.0% below the high, set on Nov 10, 2026 and 53.9% above the low. ONC is up 28.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 12.4%.

At 50.1x trailing earnings, BeOne Medicines trades above the peer-group median of 43.2x. Its forward P/E of 35.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About BeOne Medicines

Company profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. John V. Oyler
Headquarters
Basel
Employees
12,000
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, BeOne Medicines generated $5.34 billion in revenue, up 40.2% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $286.9 million, for a net margin of 5.4% versus a median of -123.9% in the prior 5 years. Gross margin was 87.5% (up from 84.4%) and operating margin 8.4%.

BeOne Medicines annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$5.34B$3.81B$2.46B$1.42B$1.18B
Growth+40.23%+54.96%+73.65%+20.37%+280.83%
Net income$286.93M$-644.79M$-881.71M$-2.00B$-1.46B
EPS (diluted)$0.19$-0.47$-0.65$-1.49$-1.21

Analyst forecast

Forecast

Consensus (27 analysts)

strong_buy

Avg. price target

$469.23+20.03%

  • Strong buy 7
  • Buy 19
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $400.00High $561.30

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.25 vs $2.34
Surprise
-89.32%

ONC news

All ONC news

BeOne Medicines peers

Health Care sector
ONC peer companies
CompanyPrice% ChgMarket capCompare
TEVATeva Pharmaceutical Industries Limited39.23+1.79%$45.77Bvs ONC
RPRXRoyalty Pharma plc Class A68.45+1.08%$39.36Bvs ONC
ZTSZoetis Inc. Class A79.11-2.08%$32.14Bvs ONC
GMABGenmab A/S ADS50.60-1.46%$31.20Bvs ONC
INSMInsmed Incorporated141.33-2.17%$31.01Bvs ONC
ROIVRoivant Sciences Ltd.38.66-0.78%$28.01Bvs ONC
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs ONC
VTRSViatris Inc.19.63-1.26%$22.50Bvs ONC

Indexes, lists and sector

BeOne Medicines stock FAQ

What is BeOne Medicines's stock price today?

ONC last traded at $390.94 as of Nov 20, 4:00 PM EST, down 2.19% on the day. Prices are delayed at least 15 minutes.

What is ONC's P/E ratio?

ONC trades at a trailing P/E ratio of 50.12 and a forward P/E of 35.93, compared with a median of 43.2 for its closest peers.

Who is BeOne Medicines's CEO?

Mr. John V. Oyler is the chief executive officer of BeOne Medicines Ltd. ADR, which has about 12,000 employees.

What is the ONC 52-week high?

The 52-week high for ONC is $424.73 and the 52-week low is $253.95. The stock is currently 8.0% below its high.

Compare ONC